Literature DB >> 21403605

Tumor microenvironment and progression of pancreatic cancer.

M Erkan1, C Reiser-Erkan, C W Michalski, J Kleeff.   

Abstract

Pancreatic ductal adenocarcinoma is characterized by « tumor desmoplasia », a remarkable increase in connective tissue that penetrates and envelopes the neoplasm. It is becoming clear that this desmoplastic microenvironment of pancreatic cancer--which is forming approximately eighty percent of the tumor mass--is not a passive scaffold for the tumor cells but an active player in carcinogenesis. Several chemotherapeutic agents and novel molecular targeted therapies against epithelial tumor cells--although showing antitumor activity in cell culture and mouse experiments--have failed to show significant effects in the clinic. Thus, targeting pancreatic tumor cells alone seems unlikely to improve the dismal prognosis of pancreatic cancer. It has recently been shown that the activated stroma of pancreatic cancer is an independent prognostic marker with an impact on patient survival as much as the lymph node status of the cancer. Several primarily benign conditions associated with expansion of stromal and inflammatory components, such as chronic pancreatitis or hereditary pancreatitis are believed to increase the risk of pancreatic cancer. Similar observations have been made in other cancer types such as chronic hepatitis-liver cancer, Barrett dyplasia-esophageal cancer, and inflammatory bowel disease-colon cancer. The common denominator of all these conditions is; chronic inflammation leads to increased incidence of cancer. In this review the impact of the activated stroma on pancreatic carcinogenesis is discussed.

Entities:  

Mesh:

Year:  2010        PMID: 21403605

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  49 in total

1.  Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1.

Authors:  Shinya Ohkouchi; Gregory J Block; Ahmed M Katsha; Masahiko Kanehira; Masahito Ebina; Toshiaki Kikuchi; Yasuo Saijo; Toshihiro Nukiwa; Darwin J Prockop
Journal:  Mol Ther       Date:  2011-12-06       Impact factor: 11.454

2.  PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker.

Authors:  Sayaka Yuzawa; Mitsunobu R Kano; Takahiro Einama; Hiroshi Nishihara
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

3.  Tie1 deficiency induces endothelial-mesenchymal transition.

Authors:  Julie Garcia; Maria José Sandi; Pierre Cordelier; Bernard Binétruy; Jacques Pouysségur; Juan Lucio Iovanna; Roselyne Tournaire
Journal:  EMBO Rep       Date:  2012-05-01       Impact factor: 8.807

4.  Changes in connexin43 expression and localization during pancreatic cancer progression.

Authors:  Joell L Solan; Sunil R Hingorani; Paul D Lampe
Journal:  J Membr Biol       Date:  2012-06-23       Impact factor: 1.843

5.  Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.

Authors:  Carolyn C Arpin; Stephen Mac; Yanlin Jiang; Huiwen Cheng; Michelle Grimard; Brent D G Page; Malgorzata M Kamocka; Sina Haftchenary; Han Su; Daniel P Ball; David A Rosa; Ping-Shan Lai; Rodolfo F Gómez-Biagi; Ahmed M Ali; Rahul Rana; Helmut Hanenberg; Kagan Kerman; Kyle C McElyea; George E Sandusky; Patrick T Gunning; Melissa L Fishel
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

6.  Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.

Authors:  Xiang-Lin Tan; Kalyan K Bhattacharyya; Shamit K Dutta; William R Bamlet; Kari G Rabe; Enfeng Wang; Thomas C Smyrk; Ann L Oberg; Gloria M Petersen; Debabrata Mukhopadhyay
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

7.  CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.

Authors:  Ajay P Singh; Sumit Arora; Arun Bhardwaj; Sanjeev K Srivastava; Madhavi P Kadakia; Bin Wang; William E Grizzle; Laurie B Owen; Seema Singh
Journal:  J Biol Chem       Date:  2012-09-20       Impact factor: 5.157

8.  Generation of an in vitro 3D PDAC stroma rich spheroid model.

Authors:  Matthew J Ware; Vazrik Keshishian; Justin J Law; Jason C Ho; Carlos A Favela; Paul Rees; Billie Smith; Sayeeduddin Mohammad; Rosa F Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean P Edwards; Stuart J Corr; Biana Godin; Steven A Curley
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

9.  A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.

Authors:  Rohit Chugh; Veena Sangwan; Satish P Patil; Vikas Dudeja; Rajinder K Dawra; Sulagna Banerjee; Robert J Schumacher; Bruce R Blazar; Gunda I Georg; Selwyn M Vickers; Ashok K Saluja
Journal:  Sci Transl Med       Date:  2012-10-17       Impact factor: 17.956

10.  Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers.

Authors:  Kenji Yokoi; Biana Godin; Carol J Oborn; Jenolyn F Alexander; Xuewu Liu; Isaiah J Fidler; Mauro Ferrari
Journal:  Cancer Lett       Date:  2012-09-18       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.